Tezepelumab Reduces Asthma Exacerbations in Patients with Severe, Uncontrolled Asthma Regardless of Season

For patients with uncontrolled, severe asthma, it is vital to have effective medications that can improve symptoms at all times of year. MILWAUKEE (PRWEB) February 07, 2022 Adults and adolescents with severe, uncontrolled asthma treated with tezepelumab experienced fewer asthma exacerbations throughout all seasons of the year compared to the placebo, according to a recent … Read more

Top NYC allergist, Dr. Clifford Bassett, cautions you can be Allergic to Valentine’s Day

Clifford W. Bassett, MD NEW YORK (PRWEB) February 07, 2022 Dr. Clifford Bassett, founder and medical director of Allergy & Asthma Care of New York (https://allergyreliefnyc.com), warns that each year, he sees a rash of patients seeking allergy care following Valentine’s Day at his Manhattan practice. “Valentine’s Day often comes with exposures that may provoke … Read more

Top NYC allergist, Dr. Clifford Bassett, cautions you can be Allergic to Valentine’s Day

Clifford W. Bassett, MD NEW YORK (PRWEB) February 07, 2022 Dr. Clifford Bassett, founder and medical director of Allergy & Asthma Care of New York (https://allergyreliefnyc.com), warns that each year, he sees a rash of patients seeking allergy care following Valentine’s Day at his Manhattan practice. “Valentine’s Day often comes with exposures that may provoke … Read more

BioCryst to Present New ORLADEYO (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, NC – BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the company will present three abstracts featuring new data on oral, once-daily ORLADEYO (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held live in Phoenix, Arizona, … Read more

Phase 1 Trial Shows Epinephrine Can Meet Therapeutic Thresholds When Administered Sublingually

The results from this study are encouraging, indicating that an epinephrine treatment alternative, which can be administered sublingually for cases of life-threatening allergic reactions, has the potential to meet the therapeutic window required to treat anaphylaxis. MILWAUKEE (PRWEB) February 03, 2022 A phase 1 study demonstrated for the first time that epinephrine can reach therapeutic … Read more

New Study Predicts Reactions to Peanut Oral Immunotherapy in Preschoolers

Shared decision-making between healthcare providers and families is essential when it comes to OIT, and the results of this study should make predicting OIT reactions a little bit easier. MILWAUKEE (PRWEB) February 02, 2022 New predictors of safety for peanut oral immunotherapy (OIT) in preschoolers will help physicians develop a personalized approach to OIT safety, … Read more

Female differences in brain development give the symptoms of the disease

A recent Yale study showed that growing astrocytes, a type of glial cell found in the central nervous system, in different types of male and female rats, differences that can affect the ability to function. the formation of neural networks or the consequences of disease. The findings were published Feb. 1 in Cell Reports. Astrocytes … Read more

4D pharma: announces additional positive data from Part A of the Phase I/II trial of MRx-4DP0004 for the treatment of asthma

– Part A of the trial achieved the primary endpoint of safety and tolerability – Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial – Company to host conference call and webcast to discuss results today at 08:00 am ET (1:00 pm GMT) Leeds, … Read more

Adobe: #SprinitoFearless this New Year

#SprintoFearless this New Year The Lunar New Year gives us a chance to set our eyes on a new year full of happiness and potential. This year marks the beginning of the Year of the Tiger, encouraging each of us to travel boldly and boldly to new lands, bound only by the limits of our … Read more

Revelation Biosciences Inc. to the first patient enrolled and enrolled in the Phase 1b Clinical Study of REVTx-99 for the treatment of rhinitis.

SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a health sciences organization that specializes in the development of immunologic drugs for the prevention and treatment of disease, in this the first patient enrolled and enrolled in a Phase 1b experimental study to evaluate the efficacy of … Read more